Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 159 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diffuse Systemic Sclerosis Clear all
Not listed No phase listed Observational

Lung Clearance Index to Identify Scleroderma Patients at Risk for ILD

NCT04535245
View directory record Official record
Conditions
Scleroderma
Interventions
LCI testing
Diagnostic Test
Lead sponsor
National Jewish Health
Other
Eligibility
21 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT03274076
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Tofacitinib, Placebo Oral Tablet
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Ann Arbor, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 21, 2026, 2:51 PM EDT
Not listed Not applicable Interventional

Novel Splinting Technique Using 3D Models

NCT05351060
View directory record Official record
Conditions
Arthritis, Osteoarthritis Hand, Scleroderma, Systemic, Scleroderma, Diffuse, Rheumatoid Arthritis
Interventions
Custom Fabricated Splint
Other
Lead sponsor
Giovanna Fichera
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Troy, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

NCT00879658
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 2 Interventional

Proof of Biological Activity of SAR100842 in Systemic Sclerosis

NCT01651143
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
SAR100842, Placebo (for SAR100842)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2016 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

NCT00419419
View directory record Official record
Conditions
Raynaud's Disease, Scleroderma, Autoimmune Diseases
Interventions
Topical AmphiMatrix with nitroglycerin (MQX-503)
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
6
States / cities
Stanford, California • Farmington, Connecticut • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 21, 2026, 2:51 PM EDT
Recruiting Phase 1 Interventional

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT06925542
View directory record Official record
Conditions
SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis
Interventions
CTX112
Biological
Lead sponsor
CRISPR Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
9
States / cities
La Jolla, California • Redwood City, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 21, 2026, 2:51 PM EDT
Active, not recruiting Not applicable Interventional

Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis

NCT06880627
View directory record Official record
Conditions
Scleroderma
Interventions
Brain Boost group, Waitlist group
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 21, 2026, 2:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optical Elastography of Systemic Sclerosis Skin

NCT02835196
View directory record Official record
Conditions
Scleroderma
Interventions
Optical Elastography, Visual Assessment
Device · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Tolerability of MEDI-551 in Scleroderma

NCT00946699
View directory record Official record
Conditions
Scleroderma
Interventions
MEDI-551, Placebo, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
12
States / cities
Loma Linda, California • Redwood City, California • Farmington, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

NCT00775463
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
treprostinil diethanolamine, placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Brentuximab Vedotin for Systemic Sclerosis

NCT03222492
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
Interventions
Brentuximab Vedotin, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT01670565
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Belimumab, Mycophenolate Mofetil, Placebo Infusion
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Not applicable Interventional Results available

Botulinum Toxin in the Treatment of Raynaud's

NCT01233999
View directory record Official record
Conditions
Raynaud's Syndrome
Interventions
botulinum toxin A
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 21, 2026, 2:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Finger Hardness Measure in Scleroderma

NCT01111786
View directory record Official record
Conditions
Scleroderma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)

NCT00442611
View directory record Official record
Conditions
Scleroderma, Diffuse, Scleroderma, Systemic
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 21, 2026, 2:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Scleroderma Registry & Repository at the Hospital for Special Surgery

NCT01656447
View directory record Official record
Conditions
Scleroderma
Interventions
Not listed
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 21, 2026, 2:51 PM EDT
Recruiting Not applicable Interventional

The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life

NCT06675344
View directory record Official record
Conditions
Systemic Sclerosis (SSc)
Interventions
Apollo Neuro Device, Sham device
Device
Lead sponsor
Robyn T. Domsic, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
New Orleans, Louisiana • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 21, 2026, 2:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis

NCT00622895
View directory record Official record
Conditions
Systemic Scleroderma, Severe Systemic Sclerosis
Interventions
fludarabine phosphate, Mycophenolic Acid, tacrolimus, total-body irradiation, bone marrow transplantation, reduced intensity allogeneic hematopoietic stem cell transplantation, quality-of-life assessment, laboratory biomarker analysis, flow cytometry, biopsy
Drug · Radiation · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
2
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Not applicable Interventional Results available

Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis

NCT01093885
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Ambrisentan
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
19 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Not applicable Interventional

Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma

NCT02837549
View directory record Official record
Conditions
Scleroderma, Ssc
Interventions
Occupational therapy treatment
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 21, 2026, 2:51 PM EDT
Completed No phase listed Observational

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

NCT00377949
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma, Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 75 Years
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
25
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 21, 2026, 2:51 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578
View directory record Official record
Conditions
Progressive Pulmonary Fibrosis
Interventions
BMS-986278, BMS-986278 Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years and older
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 70 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 21, 2026, 2:51 PM EDT